+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Chronic Kidney Disease Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 5394081
  • Report
  • July 2021
  • Region: Global
  • 114 pages
  • Mordor Intelligence
until Sep 30th 2021


  • Abbott Laboratories
  • Amgen Inc.
  • Beckman Coulter
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Siemens Healthineers
  • MORE

The Chronic Kidney Disease Market is expected to register a CAGR of 6.6 % during the forecast period.

As per the report published in 2021, 4-37% of COVID-19 cases involve the kidneys, and Acute Kidney diseases have an incidence of 50% in hospitalized COVID-19 patients. Thus, it is found that the COVID-19 virus is having an impact on the kidney of the patients, which in turn is expected to increase the burden of kidney disorder in near future, fueling the market growth.

The major factors for the growth of the chronic kidney disease market include the increasing incidence of chronic kidney diseases, technological advancements in the diagnostic tests for kidney diseases, and the rising need for early detection.

Chronic kidney disease (CKD) is a condition that causes reduced kidney function over a period of time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue. For instance, as per a 2019 report by the Center for Disease Control and Prevention, 15% of the adults in the United States, which accounts for approximately 37 million people, are estimated to have CKD.

Also, as per data state by World Kidney Day a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) in 2020, kidney disease currently affects around 850 million population worldwide. As per the estimates, one in ten adults has chronic kidney disease (CKD). The global burden of CKD is continuously increasing and is projected to become the 5th most common cause of years of life lost globally by 2040.

Immunotherapy has been gaining the attention of many companies, and it has been observed as one of the most effective treatments for kidney cancer, especially in renal cell carcinoma. In March 2017, around USD 10 million had been approved for the research studies of kidney cancer by the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP), in a federal budget of research funding in the United States. Thus, a high number of cases of chronic kidney diseases coupled with technological advancements are expected to boost the demand for the diagnosis and treatment of the products leading to the high growth of the market.

Key Market Trends

Blood Test Segment by Diagnosis is Expected to Witness a High Growth Over the Forecast Period

The major test for the diagnosis of kidney disease includes a blood test and it helps to understand how well kidneys are working. The blood test measures levels of a waste product called creatinine in the blood. The glomerular filtration rate (eGFR) is calculated to evaluate u milliliters of waste the kidney is able to filter in a minute.

Moreover, the demand for these tests is expected to increase as the incidence of CKD is high and growing in many parts of the world. The global prevalence of end-stage renal diseases (ESRD) is high and increasing at a significant rate. World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) in 2020, stated that currently around 850 million people worldwide suffer from kidney disorder and it is expected to become the 5th most common cause of years of life lost globally by 2040.

Additionally, As per a 2018 report by the L. Y. Wong et al., published in the International Journal of Nephrology, from 2007 to 2017, the prevalence of CKD increased from approximately 12% to 17% in Singapore and is further expected to increase to approximately 24% by 2035. Hence, owing to the rising prevalence of chronic kidney diseases the market is expected to witness high growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

North America held the largest market share in previous years and is anticipated to do the same in the forecast period. The major factors driving the growth of the market in the United States are developed healthcare infrastructure and the increased government initiatives, which offer lucrative reimbursement policies in the country. According to the estimates of the American Cancer Society, it is estimated that, in 2020, there would be around 73,750 new cases of kidney cancer in the United States and approximately 14,830 deaths from this disease.

As per the same source, Kidney cancer is among the 10 most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 82 (1.02%).

This indicates a big potential market demand for kidney disease diagnostics and therapeutics. Owing to the rapid increase in the incidence and prevalence of kidney diseases, the market in the United States is expected to grow, in the coming years. The market players are also focusing on the launch of new products in the market. For instance, in 2019, the U.S. Food and Drug Administration (FDA) has approved the Janssen Pharmaceutical’s drug INVOKANA (Canagliflozin) to reduce the risk of end-stage kidney disease and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease.

Also, in March 2020, the FDA has granted fast track designation for the investigation of the Boehringer Ingelheim and Eli Lilly Alliance’s SGLT2 inhibitor empagliflozin to reduce the risks for renal disease progression and cardiovascular death in adults with chronic kidney disease, according to a press release from Boehringer Ingelheim and Eli Lilly. Thus, the presence of these market propelling factors in this region is anticipated to offer lucrative growth to the market.

Competitive Landscape

The market studied is a fragmented market owing to the presence of many major market players. Some of the market players are Abbott Laboratories, Amgen Inc, AstraZeneca Plc, Beckman Coulter, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc., Siemens Healthineers, Sysmex Corporation, and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.

Note: Product cover images may vary from those shown


  • Abbott Laboratories
  • Amgen Inc.
  • Beckman Coulter
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Siemens Healthineers
  • MORE
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Chronic Kidney Diseases
4.2.2 Technological Advancements in the Diagnostic Tests for Kidney Diseases
4.2.3 Rising Need of an Early Detection
4.3 Market Restraints
4.3.1 Use of Generic Products in Few Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product Type
5.1.1 By Diagnosis Blood Tests Urine Tests Imaging Tests Others
5.1.2 By Treatment Drug Class ACE Inhibitors Angiotensin-II Receptor Blockers Diuretics Other Dialysis Others
5.2 By End User
5.2.1 Hospital
5.2.2 Diagnostic Laboratories
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AbbVie Inc.
6.1.3 Amgen Inc.
6.1.4 Bayer AG
6.1.5 Beckman Coulter
6.1.6 Bristol-Myers Squibb Company
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 GlaxoSmithKline Plc
6.1.9 Merck & Co. Inc.
6.1.10 Pfizer Inc.
6.1.11 Seattle Genetic
6.1.12 Siemens Healthineers
6.1.13 Sysmex Corporation
6.1.14 Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Beckman Coulter
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Seattle Genetic
  • Siemens Healthineers
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown